Sign up to save your podcasts
Or
Share Diana V. Do, MD / Michael A. Singer, MD - An Eye Toward Improving Outcomes in DME: Timely Diagnosis and Reduced Treatment Burden With Longer-Acting Anti-VEGF Agents
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Diana V. Do, MD / Michael A. Singer, MD - An Eye Toward Improving Outcomes in DME: Timely Diagnosis and Reduced Treatment Burden With Longer-Acting Anti-VEGF Agents
Please visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.
View all episodes
By Answers in CMEPlease visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.